Restless Legs Medication Side Effects Gambling
Mild restless legs syndrome that isn't linked to an underlying health condition can be managed with just a few lifestyle changes.
- Restless Legs Medication Side Effects Gambling Without
- Medication Restless Legs Syndrome
- Restless Legs Medication Side Effects Gambling Addiction
- Requip Medication For Restless Leg Syndrome
- Restless Legs Medication Side Effects Gambling Loss
If symptoms are more severe, medication may be needed.
Restless legs syndrome caused by an underlying health condition can often be cured by treating that condition.
Mirapex Lawsuits. A study conducted in 2003 raised concern about the possible side effects of taking Mirapex. The study, done by the Muhammad Ali Parkinson Research Center at Barrow Neurological Institute in Arizona, found that 1.5 percent of the Parkinson’s patients treated with Mirapex developed compulsive gambling behavior. A mild opiate-based painkiller, such as codeine, may be prescribed to relieve pain associated with restless legs syndrome. Gabapentin and pregabalin are also sometimes prescribed to help relieve painful symptoms of restless legs syndrome. Side effects of these.
For example, iron deficiency anaemia can be treated by taking iron supplements.
If it's associated with pregnancy, it usually disappears on its own within 4 weeks of the birth.
Lifestyle changes
A number of lifestyle changes may be enough to ease the symptoms of restless legs syndrome.
These include:
- avoiding stimulants in the evening (such as caffeine, tobacco and alcohol)
- not smoking (read more about quitting smoking)
- regular daily exercise (but avoid exercising close to bedtime)
- good sleep habits (for example, going to bed and getting up at the same time every day, not napping during the day, taking time to relax before going to bed, and avoiding caffeine close to bedtime)
- avoiding medicines that trigger the symptoms or make them worse (if you think medication is causing your symptoms, continue to take it and make an appointment to see your GP)
During an episode of restless legs syndrome, the following measures may help relieve your symptoms:
- massaging your legs
- taking a hot bath in the evening
- applying a hot or cold compress to your leg muscles
- doing activities that distract your mind, such as reading or watching television
- relaxation exercises, such as yoga or tai chi
- walking and stretching
Medication
Dopamine agonists
Dopamine agonists may be recommended if you're experiencing frequent symptoms of restless legs syndrome.
They work by increasing dopamine levels, which are often low.
Dopamine agonists that may be recommended include:
- ropinirole
- pramipexole
- rotigotine skin patch
These medications can occasionally make you feel sleepy, so you should be cautious when driving or using tools or machinery after taking them.
Other possible side effects can include nausea, dizziness and headaches.
If you experience nausea while taking a dopamine agonist, you may be given medication to help with this (antiemitic medication).
Impulse control disorder (ICD) is a less common side effect sometimes associated with dopamine agonists.
People with ICD are unable to resist the urge to do something harmful to themselves or others.
For example, this could be an addiction to alcohol, drugs, gambling, shopping or sex (hypersexuality).
But the urges associated with ICD will subside once treatment with the dopamine agonist is stopped.
Painkillers
A mild opiate-based painkiller, such as codeine, may be prescribed to relieve pain associated with restless legs syndrome.
Gabapentin and pregabalin are also sometimes prescribed to help relieve painful symptoms of restless legs syndrome.
Side effects of these medications include dizziness, tiredness and headaches.
Aiding sleep
If restless legs syndrome is disrupting your sleep, a short-term course of medication may be recommended to help you sleep.
These types of medication are known as hypnotics, and include temazepam and loprazolam.
Hypnotics are usually only recommended for short-term use (typically no longer than a week).
You may find you still feel sleepy or 'hungover' the morning after taking your medication.
Cardiovascular diseases
Recent research found people with restless legs syndrome may be more likely to develop cardiovascular disease, such as coronary heart disease or stroke, compared with people who don't have the syndrome.
This risk is thought to be greatest in people with frequent or severe symptoms of restless legs syndrome.
The exact reason for the increased risk is unclear, but it may be that the rapid leg movements are associated with an increased heart rate and blood pressure.
Restless Legs Medication Side Effects Gambling Without
Sleep problems have also been linked to cardiovascular disease.
To reduce this risk, you should exercise regularly, maintain a healthy weight, give up smoking if you smoke, and eat a healthy, balanced diet.
Read more about preventing cardiovascular disease.
Page last reviewed: 6 August 2018
Next review due: 6 August 2021
DOPAMINE AGONISTS, ROPINIROLE AND PRAMIPEXOLE, ARE THE ONLY FDA-APPROVED RESTLESS LEGS SYNDROME (RLS) THERAPIES. AS SUCH, THESE TWO dopamine agonists are considered the first line of treatment (generally at low doses) for RLS in current evidenced-based guidelines. Dopamine agonists have long been used at higher doses to treat Parkinson disease (PD), and compulsive behaviors are well known to be associated with dopamine agonist use at these levels. In a small number of case reports, however, gambling has been observed in individuals with RLS who were treated on a low dose of dopamine agonists.– In addition, Ondo and Lai reported that of 89 RLS patients treated with dopamine agonists, 7 manifested compulsive shopping behaviors and 2 manifested gambling, though none were reported to manifest the compulsive eating reported in some PD cases. The authors noted that a failure to identify similar compulsive behavioral patterns among RLS and PD patients likely related more to the higher dopamine agonist treatment range in PD rather than to specific neurobiological etiologies underlying the two disorders. Thus, Ondo and Lai speculated that the potential for RLS patients to develop compulsive behaviors may be less noticeable given the smaller doses of dopamine agonists used to treat those patients.
Here, we describe a case of a 66-year-old woman with RLS diagnosed 14 years previously. She had been treated with levodopa, ropinirole, and pergolide at various times during the course of her RLS, without improvement in her symptoms. For 7 years she was successfully managed solely on pramipexole at a maximum dose of 0.25 mg daily, but eventually the patient’s symptoms grew more intense and began occurring earlier in the day. Her neurologist recommended she increase the pramipexole dose to 1.0 mg daily. After she had been on this dosage for one year without much improvement, she was referred to the RLS specialty team at our center for a second opinion.
After a thorough history and physical exam, it was concluded that this patient’s worsening symptoms were due to either disease progression or more likely, drug-induced augmentation. Due to strong suspicion of the latter, gabapentin was started with the goal of weaning off pramipexole. A few weeks later, she sent a letter describing the “change in her habits” that only became apparent after tapering the pramipexole (see excerpt). She also reported a conscious compulsion for nocturnal eating leading to a 9-pound weight gain while on pramipexole with a documented weight loss after stopping it. Interestingly, when initially seen in clinic, this patient did not report any compulsive behaviors despite being directly questioned about them. At a follow-up clinic visit, she reported feeling like her “normal self” and her husband stated he “has his old wife back after 7 years.”
DISCUSSION
Symptoms such as compulsive behaviors are evident in people with attention deficit hyperactivity disorder, which has been linked with RLS. Yet, in this report we describe a patient with RLS with no premorbid history of attention deficit disorder or compulsive behaviors, who began to demonstrate such behaviors only in relation to dopamine agonist administration. This case also highlights the lack of patient insight into her behaviors; she only became aware of her compulsive eating and shopping after she stopped the pramipexole. Furthermore, the pramipexole dose had been relatively low (0.25 mg per day) when the compulsive shopping began, a behavior that could be corroborated by the patient’s credit card records and her husband’s account of past events.
With a low dose of dopamine agonist, our patient’s compulsive behaviors, evident only in hindsight, were not as dramatic as the reports of excessive gambling or sexual urges reported for some patients with PD taking high doses of dopamine agonists. It would not be unusual, therefore, for subtle compulsive behaviors, such as those described in this case, to go undetected initially. Even the stronger compulsive behaviors of patients with PD taking dopamine agonists are not generally seen as a problem until the consequences, such as a major loss of money, call attention to the behaviors.
The descriptions of compulsive behaviors in the PD population have led some investigators to speculate whether the behaviors result from the neurodegenerative process of PD or represent a specific effect of dopamine agonists. Demonstration of such behavior in non-PD cases and at lower doses of dopamine agonist administration suggests that subtle compulsive behaviors may be more prevalent than previously recognized by patients and treating providers. This phenomenon, which has now been reported in the RLS population, may provide additional insight into the underlying etiology of compulsive behaviors and suggest a larger neuropharmacological role played by dopamine agonists.
While most neurologists may be familiar with RLS augmentation and simple progression of the disease, many may not be aware of the aberrant behaviors that may arise in the process of treating this condition with dopamine agonists. It might be worth considering use of compulsive behavior scales during dopamine agonist treatment for RLS patients to bring attention to and further understanding of the prevalence and degree of this problem within the RLS population.
Excerpt
Medication Restless Legs Syndrome
“I heard an ad for Mirapex on TV and the word ‘compulsive’ was mentioned. Let me tell you about my problem and PLEASE keep this confidential. My husband does not know this. In the past few years I have been shopping compulsively and have now run my credit card debt up to over $40,000. Just recently, I have sat back and tried to examine why this happened. I never used to be this way. Since I started the new regimen with Neurontin I have also noticed that my behavior is not so compulsive and I am not reckless with my spending. In fact, I no longer have an interest in shopping.”
DISCLOSURE STATEMENT
This was not an industry supported study. Dr. Allen has received research support from GlaxoSmithKline and Sepracor; has consulted for GlaxoSmithKline, Boehringer Ingelheim, UCB, Xenoport, Sepracor, Novartis, Orion Pharma, Respironics, IM Systems, Pfizer, Jazz, and Schwarz Pharma; has participated in speaking engagements for Boehringer Ingelheim and GlaxoSmithKline; and has financial interests in IM Systems. Dr. Earley has received financial considerations for attendance of a meeting for Xenoport; has consulted for UCB; and has received honorarium from Boehringer Ingelheim for serving on a faculty for a symposium on RLS. Dr. Gamaldo has participated in a speaking engagement for Pfizer. Dr. Salas has indicated no financial conflicts of interest.